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RESUMEN
La solución para las tendinitis sufridas por los equinos deportivos ha sido, por años, el dilema de los médicos veterinarios que se dedican a tratar 
este tipo de lesiones. La medicina regenerativa, utilizando células madre del mismo paciente, surge como un método innovador que permite atravesar 
la barrera de resolución mantenida en el tiempo y con ventajas que superan a las terapias tradicionales, que no proporcionan una recuperación total. 
Se han descrito la médula ósea y el tejido adiposo como fuentes principales de extracción de células madre. Ambos conllevan un proceso distinto de 
concentración celular que finalmente termina como un producto que debe ser inyectado en el tendón afectado y, dadas las características típicas de 
lesión núcleo presentadas en el tejido dañado, puede ser depositado en el centro de éste. El resultado esperado es la regeneración del tendón, sin exceso 
de tejido fibroso, observando alineación de las fibras tendíneas, disminución de la infiltración inflamatoria y zona hemorrágica. Con un programa de 
rehabilitación que incluya reposo y ejercicio progresivo, el equino vuelve a su estado competitivo óptimo. La factibilidad de realizar esta terapia en 
nuestra ubicación geográfica es posible, ya que la técnica de extracción desde ambas fuentes es simple y dentro de las opciones de concentración celular, 
siendo la del tejido adiposo más sencilla ya que requiere menos elementos y menor tiempo, ejecutándose la terapia en la etapa aguda de la lesión. La 
utilización de células madre en equinos es un tema de investigación creciente, que promete resultados alentadores.
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INTRODUCTION
Horse owners, veterinarians, and the equine industry 
in general are constantly searching for new and more ef-
fective treatments for injured horses (Yingling and Nobert 
2008). Injuries during athletic activity are generally due to 
the cumulative effects of exercise and degenerative age-
related changes that have not been repaired by fibrocytes 
(Patterson-Kane and Firth 2009). These cells are highly 
differentiated that have limited potential for replication 
(Violini et al 2009). Tendons not only endure mechani-
cal stress but also they are poorly vascularized, and the 
metacarpal SDFT (Superficial Digital Flexor Tendon) 
has a smaller cross-sectional area in its central region, 
which also may contribute to its susceptibility to injuries 
(Patterson-Kane and Firth 2009).
Of all sporting horses, polo horses are more to exposed 
to injuries in the metacarpal phalangeal joint, tendons and 
the ligamentous structures of the palmar region. The game 
of polo has an emphasis on speed, violent turns and sudden 
stops that make this activity very demanding (Tuemmers 
and Moran 2005). Sports statistics indicate that tendinitis 
is the most common cause of fractures, which are often 
career-ending for a Thoroughbred (Nixon et al 2008).
The injuries in horses are broadly classified as result-
ing from extrinsic or intrinsic damage. Extrinsic injury 
is frequently associated with a sharp laceration or a 
traumatic blow that physically damages the ECM and/or 
cells. Intrinsic damage is associated with a degenerative 
condition within the tendon or ligament proper (Dahlgren, 
2007). After a rupture, overlapping phases of reactivation 
of inflammation, proliferation, remodeling and maturation 
do not necessarily regenerate normal structure and function, 
which results in long-term persistence of scar tissue and a 
high incidence of new lesions (Patterson-Kane and Firth, 
2009, Herthel, 2001). The stress on the injured tendon, 
induced by athletic endeavors in both horses and humans, 
often inhibits the return to previous activity levels (Violini 
et al 2009). In addition, the recurrence of tendinitis after 
returning to competition can be up to 43% (Dyson 1997).
Decades of experience have demonstrated in vivo that 
tendon and ligament regeneration and repair are slow and 
inefficient after injury (Violini et al 2009). Bi et al (2007) 
affirmed that the repair of injured tendons remains as a 
considerable challenge, mostly due to the lack of knowledge 
in the characterization of tendon cells and their precursors.
Cell therapy is one of the most recent approaches 
to regenerative medicine, where this therapy aims to 
replace or repair damaged organs and tissues (Ferrari et 
al 2007). Mesenchymal stem cells (MSCs) have been 
investigated recently for their potential for use in regen-
erative medicine (Violini et al 2009). Multipotent stem 
cells are the precursors of specialized cells in specific 
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tissues (Zaidi and Nixon 2007). Adult stem cells treated 
with specific factors represent a promising method for 
the use of tenocytes developed in vitro for tendon healing 
(Violini et al 2009).
MSCs appear to be a promising tool for cell therapy 
because of the characteristics they share with embryonic 
stem cells, in addition to advantages in terms of availabil-
ity, scalability, transplantability and ethical implications 
(Krampera et al 2006, Murphy et al 2003). In the United 
States, the discussion of stem cell therapy is currently over-
shadowed by the ongoing political debate over embryonic 
stem cell research, as it was initially thought that embryos 
were the only viable source of stem cells (Yingling and 
Nobert 2008). In Latin America, understanding of the 
processes related to cell therapy and of MSC biology is 
still in the early stages (Pineda and Londoño 2009). The 
aim of this study is to describe the features, techniques 
for extraction, processing, application and effects of the 
stem cells therapy in tendon injuries in sportive horses.
CELL THERAPY: MESENCHYMAL STEM CELLS
Research on the use of MSCs in tissue regeneration has 
generally been driven by the needs of human medicine; 
however, the nature, prevalence and prognosis of superfi-
cial digital flexor tendinitis have placed equine veterinary 
science at the forefront of tendon regeneration research 
(Taylor et al 2007). MSCs derived from adult tissues have 
emerged as a potential injectable multipotent cell treat-
ment. Under this treatment paradigm, the injected cells 
would have the capacity to differentiate and participate 
in the repair of various musculoskeletal tissues, including 
tendons. The long-term viability of these cells in tissue 
would yield lasting effects (Zaidi and Nixon 2007, Zuk et 
al 2002, Taléns-Visconti et al 2006, Hildebrand et al 2002).
The term “MSC” encompasses several heterogeneous 
groups of migratory cells in the body. All of these are cells 
that have left their original stem cell clusters and thus belong 
to a large pool of transitional cells that have the ability to 
renew themselves after trauma, disease or aging (Kruegel 
et al 2008, Pittenger et al 1999). Tissue injury that causes 
changes in the microenvironment may be one signal that 
induces stem cells intrinsic to the injured tissue to replace 
the existing necrotic cells (Bianchi Di Risio et al 2004).
The old belief that stem cell differentiation into a 
particular lineage is limited to the organ in which the 
cells are found has been replaced by evidence that MSCs 
are endowed with great plasticity that allows them to 
differentiate into a variety of tissues (Bianchi Di Risio et 
al 2004). These tissues include bone, cartilage, muscle, 
ligaments, tendons, adipose tissue and bone marrow stroma 
(Hildebrand et al 2002).
From the point of view of their reproductive capacity 
and function, MSCs have been defined as those that can 
divide for the purpose of self-renewal, producing more 
MSC like them, but also generate daughter cells committed 
to different cell lineages of functionally and morphologi-
cally specialized cells (Hernández and Dorticós 2004).
In adults, there are multipotent cells that originate from 
numerous mesenchymal tissues, such as bone marrow, 
perivascular tissue, blood, tendon, muscle and adipose 
tissue, any of which may potentially be used as a source 
of autogenous multipotent cells for transplantation (Bi 
et al 2007). However, according to Vidal et al (2006), a 
greater quantity of MSCs can be obtained in young animals.
Stem cells derived from adult tissues may participate 
in the regeneration of damaged tissue via two different 
mechanisms: the direct mechanism, which involves the 
phenotypic differentiation of tissue-specific cells, and 
the indirect mechanism, which involves the generation 
of tissue-specific extracellular matrix products (paracrin 
effect) (Nixon et al 2008). Differentiation and self-renewal 
of stem cells are regulated by specific cells in their envi-
ronment (Bi et al 2007). Furthermore, according to Agung 
et al (2006), MSCs are able to move to the site of injury 
and contribute to tissue regeneration. Therefore, the use 
of autologous cells has an added benefit, as it does not 
incite a host immune response (Hildebrand et al 2002). 
These cells have been described as immunoregulatory or 
immunoprivilegiate because they are able to escape immune 
recognition and inhibit host defense mechanisms (Vinatier 
et al 2009, Tyndall and Uccelli 2009).
The above mentioned characteristic is the reason why 
the digital flexor tendon injuries in horses have an etio-
pathogeneses that differ from those of laceration injuries, 
but are ideal for the implementation of MSC therapy, as 
they provide a core within the lesion that can maintain 
implanted MSCs without the need for external support 
(Smith 2004).
However, regardless of the type of treatment selected, 
extended rest, with gradual increase of controlled exercise, 
is the cornerstone of successful recovery (Nixon et al 2008). 
It is observed that, the exercise can increase the capacity of 
tenocytes to repair microdamage (Kasashima et al 2007).
CHARACTERISTICS OF STEM CELLS
ORIGIN AND POTENTIAL
During early embryonic development, some of the 
embryonic stem cells from the inner cell mass of the 
blastocyst develop into mesoderm (Kruegel et al 2008, 
Koch et al 2008). These cells are progenitors of the adult 
mesenchymal cells that make up connective tissues such 
as bones, tendons, muscle and cartilage. Some of these 
embryonic mesenchymal cells are believed remain mul-
tipotent in each tissue (Kruegel et al 2008).
The biological property that best characterizes MSCs 
is their unique capacity to differentiate into osteoblasts, 
adipocytes and chondroblasts under standard differentia-
tion culture conditions for tissues in vitro (Dominici et al 
2006, Schnabel et al 2009). In the body, MSCs are able 
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to self-renew and differentiate in a multipotent manner, 
depending on the precise regulatory conditions present in 
that area (Wang et al 2009).
Tenocytes are fibroblast cells responsible for matrix 
synthesis; it is thought that the stimulus for the differentiation 
of MSCs into tenocytes is a combination of mechanical 
tension, metabolic signals and contact with the surrounding 
cells and matrix (Patterson-Kane and Firth 2009, Smith 
2004). MSCs produce and adhere to extracellular matrix 
molecules (Conget and Minguell 1999). Krampera et al 
(2006) found that upon injection of intravenous MSCs, 
the cells diffuse into all tissues, but preferentially survive 
and proliferate in the presence of regenerating tissues and 
tumors, where the MSCs develop into vascular-stromal 
fibroblasts.
STEM CELL MORPHOLOGY
MSCs are characterized by a spindle morphology, an 
elongated, central nucleus containing 2-3 small nucleoli 
(< 6 mm) and primitive, unorganized euchromatin. (Flores 
et al 2006, Vidal et al 2006, Ratajczak et al 2008, Violini 
et al 2009).
In culture, MSCs have a population doubling time of 
33 hours, a strong proliferative potential and a variety of 
distinctive cell cycle characteristics, including a subset 
(20%) of cells that remain quiescent (inactive); these cells 
maintain a steady supply of cells which, via proliferation 
and delivery, can serve as precursors to a number of non-
hematopoietic tissues (Conget and Minguell 1999).
SOURCES OF STEM CELLS
Several studies have isolated non-hematopoietic cells 
from bone marrow and cultured them in vitro, calling them 
“mesenchymal” cells because of their similarity to the 
mesenchymal tissue of the embryo, where these cells can 
be induced to form cell lines that will differentiate into new 
tissues (Bianchi Di Risio et al 2004, Baghavan et al 2009).
Adipose tissue contains a stromal vascular fraction 
(SVF), which is an accessible and abundant source of 
MSCs for cell therapy applications, such as tissue repair 
(Oedayrajsingh et al 2007, Taléns-Visconti et al 2006). 
Vidal et al (2007) described for the use of adipose tissue 
derived MSCs in tissue engineering for equine veterinary 
medicine.
It has been demonstrated that human and mouse 
tendons house a population of cells called tendon stem/
progenitor cells (TSPCs), which possess universal stem 
cell characteristics such as clonogenicity, multipotency 
and self-renewal capacity (Bi et al 2007).
CELL SURFACE MARKERS OF STEM CELLS
Interactions between cell surface receptors and their 
ligands are essential for cell attachment, communication 
and function (Majumdar et al 2002). Thus, surface phe-
notype, in conjunction with other functional criteria, can 
be used to better identify MSCs (Dominici et al 2006).
MSCs express CD13, CD29, CD44, CD71, CD90, 
CD105/SH2 (endoglin) and SH3 (Zuk et al 2002, De 
Mattos et al 2009). MSCs display an immunophenotype 
that is negative for the hematopoietic and endothelial 
markers CD14, CD34, CD45, CD31, vWF and HLA II 
(Zhang et al 2009). HLA-DR molecules are not expressed 
in MSCs unless the cells are stimulated to express them, 
as by IFN-γ (Dominici et al 2006). Anderssen et al 2001, 
reported that stem cell they used in their research, are 
immunoreactive for nestin.
The discovery that MSCs from equine bone marrow 
express Oct4, Sox-2 and Nanog could indicate that the 
distinction between embryonic and adult markers is not as 
strict as originally thought, and that adult MSCs may also 
have the capacity to differentiate into tenocytes (Violini 
et al 2009, Zhang et al 2009).
After exposure of bone marrow MSCs to BMP-12, 
the MSCs expressed two tendon cell surface markers: te-
nomodulin and decorin (Violini et al 2009). TSPC (tendon 
stem/progenitors cells) express factors closely related to 
the tendon, such as SCX, TNMD, Comp and tenascin C 
(Bi et al 2007).
FEATURES OF THE ADIPOSE TISSUE AS A 
SOURCE OF MSCS
Adipose tissue is a complex mixture of cells, consisting 
of adipocytes, fibroblasts, vascular smooth muscle cells, 
endothelial cells and immune cells, as well as stem cells 
(TaPp et al 2008, Rehman et al 2004). Adipose tissue 
represents an accessible source of mesenchymal stem 
cells with characteristics similar to those of stem cells 
derived from bone marrow (Taléns-Visconti et al 2006, 
Zuk et al 2002). Moreover, Vidal et al (2007) argue that 
adipose tissue is a potential source of adult stem cells 
for use in tissue engineering for applications in equine 
regenerative medicine.
Stem cells derived from adipose tissue can readily be 
made available in large quantities. Minimal morbidity and 
discomfort are associated with harvesting the cells (Zuk 
et al 2001). Coccygeal fat at the base of the tail represents 
the most accessible site in horses with strong muscles, 
and it can be surgically removed using sedatives and local 
anesthesia (Nixon et al 2008).
Adipose-derived autologous stem cells (ASC) can be 
isolated relatively rapidly from adipose tissue via collagenase 
digestion (Vidal et al 2007). These harvested autologous 
cells are immunocompatible with the patient, and there 
are no ethical problems associated with their use, as the 
use of embryionic stem cells (Zuk et al 2001). The isola-
tion of the fraction of nucleated cells from fat provides a 
pool of cells for immediate injection into lesion sites or 
for future use in propagation culture, where they can be 
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maintained as a reserve of adipose-derived nucleated cells 
(Nixon et al 2008).
The performance of adipose cells can be influenced by 
age and tissue collection site (Vidal et al 2007, Colleoni 
et al 2009). The yield of nucleated cells derived from 
adipose tissue ranged from 1.47 x 106 cells/g to 2.71 x 106 
cells/g (mean ± SD, 2.30 ± 0.57 x 106 cells/g) (Nixon et 
al 2008). In the case of liposuction, yields are generally 
between 50 and 400 x 106 cells, which can be amplified 
at least 10-fold within 1 week (Rehman et al 2004). The 
viability of cells after digestion ranged from 83% to 91% 
(mean, 87.5%) (Nixon et al 2008).
Nixon et al (2008) injected adipose-derived nucleated 
cell fractions and observed no adverse effects resulting 
from the injection. The range of time from the collection 
of adipose tissue to the injection of adipose-derived nucle-
ated cells ranged from 40 to 53 hours. The mean ± SD 
(standard deviation) number of adipose-derived nucleated 
cell fractions derived from adipose tissue in each syringe 
was 13.83 ± 3.41 x 106 cells. On the basis of these data, 
adipose tissue may represent a source of stem cells that 
could have important consequences in several fields (Zuk 
et al 2002).
It is possible that the stem cells derived from adult 
tissues indirectly contribute to recovery by producing 
bioactive proteins such as growth factors, anti-apoptotic 
factors and chemotactic agents (Rehman et al 2004). These 
hidden proteins have important effects on local cell dy-
namics, stimulating vascular ingrowth and the recruitment 
of additional stem cells capable of stimulating recovery 
(Nixon et al 2008, Rehman et al 2004). Additionally, 
one of the most important adipocytokines produced by 
adipocytes is adiponectin, which has anti-inflammatory 
effects on endothelial cells; adiponectin inhibits the TNF 
induced by the expression of adhesion molecules, and 
interferes with the macrophage phagocytic function (Tilg 
and Moschen 2006).
Kisiday et al (2007) argued that adipose-derived cells 
have high rates of synthesis of extracellular matrix by 
wet weight, which is four times that of cell aggregation. 
These results suggested a repair potential per cell that is 
significantly lower than that of the MSCs derived from 
bone marrow, notwithstanding that the described study 
was performed to repair cartilage.
MESENCHYMAL STEM CELLS FROM BONE 
MARROW
Bone marrow is a complex, sinusoidal and well-
organized tissue located in the marrow cavity of the long 
bones, sternum, hip bones and spongy vertebrae, making 
it one of the major tissues of the body. Its main function is 
to promote hematopoiesis (Di Risio Bianchi et al 2004). In 
the complex cellular structure found in the bone marrow 
stroma, there is a subset of non-hematopoietic cells com-
monly referred to as bone marrow MSCs, which exhibit 
98% morphological uniformity in culture (Conget and 
Minguell 1999, Bianchi Di Risio et al 2004).
MSCs can be isolated from bone marrow and repro-
duced more than 1 billion-fold in cell culture, and gene 
transcripts can be harvested without affecting their dif-
ferentiation potential (Hildebrand et al 2002, Baghavan 
et al 2009). Most clinical trials that have used bone 
marrow cells, however, report that the cells are available 
only in limited quantities and cannot be easily amplified 
(Rehman et al 2004).
It has been shown that equine bone marrow-derived 
MSCs play a central role in the repair and regeneration 
of mesenchymal tissues, and thus that they may be in-
duced to differentiate into tenocytes (Violini et al 2009, 
Hankemeier et al 2005). Without specific differential 
induction, however, therapeutic use of these cells could 
potentially lead to ossification, exacerbating the tendinopa-
thy (Bi et al 2007). Other potential drawbacks in the use 
of bone marrow aspirates to provide a pool of MSCs for 
therapeutic purposes include the pain associated with the 
collection process, low cell yield and pneumothorax and 
pericardial lacerations during bone marrow harvest from 
the sternum (Nixon et al 2008, Zuk et al 2001, Vidal et 
al 2007). Thus, the clinical use of bone marrow-derived 
stem cells may be harmful to the donor due to the highly 
invasive collection procedure. Furthermore, bone marrow 
aspirates may contain few stem cells (Kern et al 2006, 
Wang et al 2009, Nixon et al 2008).
From a practical standpoint, the low number of stem 
cells harvested necessitates an ex vivo expansion stage to 
obtain a clinically significant number of cells. This step is 
slow and expensive, and it risks contamination of the line 
and loss of cells (Zuk et al 2001). Pittenger et al (1999), 
however, obtained positive results after 1-3 weeks in 
lineage-specific culture media without evidence of other 
lines in the culture.
In bone marrow, adult stem cells are found at a 
prevalence of 1 stem cell in 100,000 bone marrow 
nucleated cells (Zaidi and Nixon 2007). The separation 
of bone marrow aspirates collected from adult horses 
resulted in a harvest of 6.4 ± 3.4 x 106 nucleated cells/
ml of aspirate. Cell viability after thawing of primary 
colt MSCs stored in liquid nitrogen of was 64 ± 6% 
(Vidal et al 2006).
TECHNIQUES FOR EXTRACTION, PROCESSING 
AND APPLICATION OF NUCLEATED CELL 
FRACTIONS
PRIMARY SOURCE: ADIPOSE TISSUE
Step 1: Aseptic cleaning, patient sedation and desensiti-
zation of the area. Vidal et al (2007) suggest that horses 
should be sedated with detomidine HCl (0.04 mg/kg 
intravenous [IV]) and butorphanol (0.01 mg/kg IV), that 
the area along the dorsal gluteal muscle and skin with 
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subcutaneous tissue should be prepared aseptically , and 
that the area should be numbed with local application of 
lidocaine 2%, using an inverted L block.
Step 2: Harvest of adipose tissue.
A) Surgical extraction: The paraxial caudodorsal glu-
teal region is opened (Nixon et al 2008). Subcutaneous 
adipose tissue is collected from above the dorsal region 
of the gluteal muscle (Vidal et al 2007). A linear incision 
10-15 cm long is made from about 10 cm abaxial to the 
vertebral column and 10 cm cranial to the tail head; the 
incision should be centered in the groove formed by the 
proximal origin of the biceps femoris and semitendinosus. 
About 15-20 g of subcutaneous adipose tissue is then 
dissected using curved scissors. Next, the skin incision is 
closed with 0 polypropylene, using a simple interrupted 
suture pattern or a Ford interlocking pattern. It is recom-
mended to provide NSAIDs for 3 days after harvesting 
the adipose tissue (Nixon et al 2008).
B) Alternative collection method: liposuction. Method 
as described in humans. In this procedure, a hollow 
blunt cannula is introduced into the subcutaneous space 
through small incisions (1 cm). The cannula is con-
nected to gentle suction and moved through the adipose 
compartment, mechanically disrupting the fat tissue. A 
saline solution and epinephrine (as a vasoconstrictor) 
are infused into the fat compartment to minimize blood 
loss and tissue contamination by peripheral blood cells 
(Zuk et al 2001).
Step 3: Fat sample processing.
A) Procedure from surgical extraction. The adipose 
tissue sample is placed in a 50-mL falcon tube contain-
ing sterile phosphate-buffered saline solution (PBS) and 
maintained at 4 °C (Nixon et al 2008). The sample is 
ground with a surgical blade, washed and briefly stirred 
with an equal volume of buffer solution (PBS) to promote 
the separation into 2 phases. The upper phase consists of 
ground and washed adipose tissue, and the infranatant 
fluid contains hematopoietic cells suspended in PBS. This 
fluid is removed (Vidal et al 2007).
The tissue is then digested in an equal volume of 
filtered PBS solution containing 1% bovine serum 
albumin and 0.1% collagenase type I, with continuous 
stirring at 37  °C for 50 minutes (Vidal et al 2007). 
Subsequently, suspensions are filtered with 500 μm 
and 250 μm Nitex (Rehman et al 2004). To complete 
the separation of the stromal cells from the primary 
adipocytes, the sample is briefly and vigorously stirred, 
then centrifuged at 260 x g for 5 minutes, resulting in 
an SFV pellet containing nucleated cells and an adipose 
tissue fraction, which can be discarded. The stem cells 
can then be harvested (Awad et al 2003, Danišoviþ et 
al 2007, Vidal et al 2007).
The SFB pellet is resuspended in 160 mm NH4Cl and 
incubated at room temperature for 10 minutes to lyse the 
blood cells, and the solution is centrifuged at 300 g for 5 
minutes, resulting in an injectable product (Nixon et al 
2008, Rehman et al 2004, Taléns-Visconti et al 2006).
Step 4: Application of adipose-derived nucleated cell 
fractions in tendon. After isolation and purification, the 
adipose-derived nucleated cell fractions pellet derived 
from adipose tissue is resuspended in 0.6-mL aliquots 
of sterile PBS solution and loaded into 3 sterile syringes 
labeled with the data and ID of the donor horse. Then, 
clip the leg to be implanted to include subcarpal local 
anaesthetic sites. Subsequently, the upper middle meta-
carpal area of the each horse’s injured tendon is prepared 
for aseptic injection with three 22-gauge needles. Using 
ultrasound guidance to give a side view of the SDFT 
ensures the entry of the needle into the center of the 
lesion. The needles are placed approximately 1 cm apart, 
beginning 15 cm distal to the accessory carpal bone and 
moving progressively distally. A sterile dressing is then 
applied (Nixon et al 2008).
Figure 1: Site of extraction of adipose tissue.
 Sitio de extracción de tejido adiposo.
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SECONDARY SOURCE: BONE MARROW
Step 1: Cleaning and patient sedation. The collection is 
prepared aseptically. Violini et al (2009) aseptically ob-
tained samples of bone marrow (BM) from the sternum, 
maintaining general anesthesia during surgery, and Pacini 
et al (2007) obtained bone marrow aspirates via sternal 
puncture under local anesthesia with a subcutaneous injec-
tion of 5 ml of lidocaine (2%).
Step 2: Bone marrow harvesting and surgical extraction. 
Intersternebral spaces are easily identified via ultrasound. 
Bone marrow needles are used for marrow aspiration into 
two 20-mL syringes containing 30,000 units each of sodium 
heparin. Immediately after collection, samples are stored 
on ice (Violini et al 2009). Kasashima et al 2011, suggests 
that the most practical and safest site to aspirate bone 
marrow is from the 5th sternebra, as it is sufficiently caudal 
to avoid the cranial ventral bony crest, which covers the 
first 3 sternebrae and is easily accessible and identifiable.
Step 3: Sample processing. The bone marrow sample (30 
mL) is placed in a Hystopaque ™ 1077 (Sigma Aldrich, 
St. Louis, MO) tube and centrifuged for 20 minutes at 400 
g at 4 °C. The supernatant MSC-enriched cell population 
is aspirated and then washed in magnesium- and calcium-
free PBS, then centrifuged at 260 g for 5 min at 4 °C. The 
cell pellet is then resuspended in 10 ml of Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 
10% fetal calf serum (FCS), penicillin (100 U/ml) and 
streptomycin (100 μg/ml) (P/S) and 1% nonessential 
amino acids. Next, the cells are seeded in 24-well plates 
(Violini et al 2009). The medium, containing 50 ng/mL 
epidermal growth factor (EGF), is changed every 2-3 
days, and non-adherent cells are removed (Violini et al 
2009, Zhang et al 2009).
Step 4: Culture for amplification of stem cells. After 2 
weeks, when cells are actively dividing, they are quantified 
and seeded in T25 flasks (4 × 105 cells/flask) or 24-well 
plates (2 × 105 cells/ml) and incubated at 37 °C, with 5% 
CO2 (Violini et al 2009).
Step 5: Induction of differentiation. Although this step 
is not necessary, Violini et al (2009) suggest that when 
bone marrow-derived MSCs achieve 70% confluence, 
the cells should be trypsinized, counted and plated at a 
density of 6 × 105 in a culture flask T25. To induce dif-
ferentiation into tenocytes, cell cultures are maintained 
for 14-21 days in culture medium supplemented with 
BMP-12 50 ng/mL.
Step 6: Therapeutic application. This step is similar to 
step 4 (described above) for adipose tissue.
EXPECTED RESULTS OF ADIPOSE TISSUE-
DERIVED NUCLEATED CELLS TREATMENT
The tendons treated with adipose-derived nucleated 
cells, show significant clinical improvement, as indicated 
by the linearity and uniformity of the collagen fibers 
observed via ultrasound examination, the appearance 
of striations under polarized light microscopy, a reduc-
tion in the infiltration of WBCs (white blood cells), and 
no evidence of bleeding and a smoother surface on the 
epitenon. The expression of collagen type I show no 
obvious changes after treatment; however, the expres-
sion of collagen type III is evident in healed tendon 
and is reduced in tendons treated with adipose-derived 
nucleated cells. The expression of COMP (cartilage 
oligomeric matrix protein) is significantly increased in 
tendons treated with MSCs derived from adipose tissue 
(Nixon et al 2008).
EXPECTED RESULTS OF TREATMENT WITH 
BONE MARROW-DERIVED MSCS
Pacini et al (2007) observed that 9 out of 11 animals 
treated with MSCs achieved full recoveries, as shown by 
ultrasound images of the tendons taken after a period of 
3-6 months, when they returned to racing. The horses even 
achieved competitive results in the same competitive tiers 
they had raced in prior to injury. Furthermore, the horses 
went 9-12 months without recurrence of injury, and 9 out 
of 10 showed increased density of the tendon, indicating 
the initial stages of repair after only 1 month. Six months 
after the injection of mesenchymal cells, the tendons ap-
peared to be almost completely repaired.
Figure 2: Aspiration of bone marrow technique from the sternum 
(Kasashima et al 2011).
 Técnica de aspiración de medula ósea desde esternón. 
(Kasashima et al 2011).
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Lacitignola et al (2008) conducted a study on cell 
therapy for tendinitis in horses with collagenase-induced 
tendinitis. In this study, the transplantation of MSCs 
derived from bone marrow produced regeneration of the 
extracellular matrix of tendons by enhancing the rates of 
production of collagen type I/III, and expression of COMP 
and improving fiber orientation. In parallel, the same authors 
conducted a clinical study to verify the clinical efficacy of 
autologous grafting of MSCs derived from bone marrow 
into spontaneous lesions (resulting from excessive tension) 
of ligaments and tendons in horses. The subjects were 
observed for a minimum of 16 weeks and a maximum of 
150 weeks after treatment, with an average of 48 weeks 
of follow-up observation. All animals exhibited the same 
result: there was no swelling or inflammatory response 
after implantation of MSCs derived bone-marrow. Three 
weeks after treatment, researchers found no pain in response 
to digital pressure at the site of injury. At 6 weeks, and 
through subsequent follow-ups, no lameness was evident 
upon clinical examination. The lesions began to improve 
after 3 weeks. CSA-L (cross sectional area of the lesion), 
FPS (fiber pattern score) and TLS (type lesion score) 
improved in all patients, with an appreciable filling-in of 
the lesions, indicated by a decrease in the CSA-l and an 
increase in TLS. This trend remained consistent through 
subsequent follow-ups. When the horses started the exercise 
program, the tendon architecture, as measured by its length 
and longitudinal alignment, also improved. At the time of 
reporting, 12 subjects (60%) had returned to racing and 8 
(40%) were training under a controlled exercise program. 
It was observed a recurrence of injury of 35%, and all 
owners rated the outcome (in terms of sporting success) 
from good to excellent (Lacitignola et al 2008).
CONCLUSION
It is relevant to emphazise this therapy as an interest-
ing, effective and efficient method which in fact has not 
been intensively developed in our country yet. Different 
sources of stem cell extraction, mainly bone marrow and 
adipose tissue, from the same patient in question could 
be used for the treatment of tendons in sport horses. They 
can present certain advantages and disadvantages over 
other sources, mainly due to the number of nucleated cells 
which is higher in adipose tissue while the extraction of 
bone marrow could be a very invasive process.
It is suggested to expand and to polish the procedure 
by incorporating protocol, identification of extracted cell 
contents, filtered and purified, as well as to make cell 
amplification and application of diverse pathological 
conditions that require tissue regeneration.
Therefore, regenerative therapy is presented as a 
therapeutic tool that can provide a solution to the constant 
concern of breeders, veterinarians and owners of sport 
horses regarding frequent locomotor problems of their 
animals, such as tendinitis.
SUMMARY
Finding a cure for tendonitis in sporting horses has been a challenge 
for veterinarians during a long time. Regenerative medicine using stem 
cells from the patient has emerged as an innovative method that allows 
breaking the barriers of finding a resolution that can be maintained over 
time. Additionally, the benefits surpass those of traditional therapies, 
which do not facilitate full recovery. Bone marrow and adipose tissue 
have been described as major sources for stem cell extraction. The 
use of both tissues involves different processes of cell harvesting and 
concentration, which eventually yield a product that must be injected 
into the affected region, or in the center of a typical core lesion. The 
expected result is the regeneration of the tendon without excess fibrous 
tissue, properly aligned tendon fibers and decreased inflammatory 
infiltration and hemorrhage. Following a rehabilitation program that 
includes resting and progressive exercise, the horse returns to its previous 
competitive condition. This therapy is feasible because the techniques 
for extraction from both sources are simple. If the two techniques are 
compared, adipose tissue extraction is easier because it requires fewer 
elements and less time. Both therapies, however, can be executed in the 
acute stage of injury. The use of stem cells in horses is the subject of 
a growing body research that has already yielded encouraging results.
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